Reading ILMN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ILMN free→Reading ILMN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ILMN free→QuarterlyIQ Insights · ILMN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 29, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…
Other Events. On April 28, 2026, the Company’s Board of Directors authorized a new share repurchase program for up to $1.5 billion of the Company’s common stock (the “2026 Repurchase Program”). The 2026 Repurchase Program is in addition to the $1.5 billion repurchase program authorized by the Board of Directors in August 2024, under which approximately $314 million of repurchase capacity remained as of April 29, 2026. Table of Contents
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 2, 2026, each of Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board of Directors (the "Board") of Illumina, Inc. (the "Company") of her or his intention to retire as a director of the Company, effective as of May 21, 2026 (the date of the Company’s 2026 annual meeting of stockholders). The retirements of Drs.…
Results of Operations and Financial Condition. On February 5, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…
Completion of Acquisition or Disposition of Assets. As previously disclosed in the Current Report on Form 8-K filed by Illumina, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on June 23, 2025, the Company entered into a Stock Purchase Agreement, dated as of June 22, 2025 (the “Purchase Agreement”), with Standard BioTools Inc. (“Standard BioTools”), a Delaware corporation, pursuant to which the Company agreed to acquire (the “Transaction”) from Standard BioTools…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.